Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 7:17 pm Purchase | 2026-02-09 | 13G | Galecto, Inc. GLTO | Venrock Healthcare Capital Partners III, L.P. | 3,603,595 6.000% | 3,603,595 (New Position) | Filing History |
| 2026-02-17 6:22 pm Purchase | 2025-12-31 | 13G | Vor Biopharma Inc. VOR | Venrock Healthcare Capital Partners III, L.P. | 2,216,075 9.900% | 1,455,376 (+191.32%) | Filing History |
| 2026-02-17 6:20 pm Purchase | 2025-12-31 | 13G | Tenax Therapeutics, Inc. TENX | Venrock Healthcare Capital Partners III, L.P. | 692,959 9.900% | 139,989 (+25.32%) | Filing History |
| 2026-02-17 6:18 pm Purchase | 2025-12-31 | 13G | Savara Inc. SVRA | Venrock Healthcare Capital Partners III, L.P. | 20,881,288 9.900% | 8,200,245 (+64.67%) | Filing History |
| 2026-02-17 6:17 pm Sale | 2025-12-31 | 13G | Perceptive Capital Solutions Corp Class A Ordinary Shares PCSC | Venrock Healthcare Capital Partners III, L.P. | 0 0.000% | -750,000 (Position Closed) | Filing History |
| 2026-02-17 6:15 pm Sale | 2025-12-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC | Venrock Healthcare Capital Partners III, L.P. | 5,676,230 5.800% | -920,655 (-13.96%) | Filing History |
| 2026-02-17 6:13 pm Sale | 2025-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Venrock Healthcare Capital Partners III, L.P. | 6,862,972 3.200% | -6,050,448 (-46.85%) | Filing History |
| 2026-02-17 6:11 pm Purchase | 2025-12-31 | 13G | Jade Biosciences, Inc. JBIO | Venrock Healthcare Capital Partners III, L.P. | 5,115,862 9.900% | 1,895,493 (+58.86%) | Filing History |
| 2026-02-17 6:09 pm Sale | 2025-12-31 | 13G | enGene Holdings Inc. ENGN | Venrock Healthcare Capital Partners III, L.P. | 4,771,414 7.100% | -275,000 (-5.45%) | Filing History |
| 2026-02-17 6:05 pm Purchase | 2025-12-31 | 13G | Crescent Biopharma, Inc. CBIO | Venrock Healthcare Capital Partners III, L.P. | 2,666,064 9.500% | 2,666,064 (New Position) | Filing History |
| 2026-02-17 6:04 pm Purchase | 2025-12-31 | 13G | CASI Pharmaceuticals, Inc. CASI | Venrock Healthcare Capital Partners III, L.P. | 1,987,259 9.200% | 480,219 (+31.87%) | Filing History |
| 2026-02-11 5:11 pm Purchase | 2026-02-04 | 13G | Adlai Nortye Ltd. ANL | Venrock Healthcare Capital Partners III, L.P. | 9,638,193 6.100% | 9,638,193 (New Position) | Filing History |
| 2026-01-16 4:32 pm Purchase | 2026-01-09 | 13G | Century Therapeutics, Inc. IPSC | Venrock Healthcare Capital Partners III, L.P. | 13,043,478 7.100% | 9,086,292 (+229.61%) | Filing History |
| 2025-11-14 5:38 pm Purchase | 2025-09-30 | 13G | Tenax Therapeutics, Inc. TENX | Venrock Healthcare Capital Partners III, L.P. | 552,970 9.900% | 197,746 (+55.67%) | Filing History |
| 2025-11-14 5:37 pm Purchase | 2025-09-30 | 13G | Savara Inc. SVRA | Venrock Healthcare Capital Partners III, L.P. | 12,681,043 7.300% | 3,659,536 (+40.56%) | Filing History |
| 2025-11-14 5:35 pm Purchase | 2025-09-30 | 13G | Oruka Therapeutics, Inc. ORKA | Venrock Healthcare Capital Partners III, L.P. | 4,909,619 9.900% | 761,191 (+18.35%) | Filing History |
| 2025-11-14 5:34 pm Sale | 2025-09-30 | 13G | Ocular Therapeutix, Inc. OCUL | Venrock Healthcare Capital Partners III, L.P. | 12,913,420 7.300% | -846,780 (-6.15%) | Filing History |
| 2025-11-14 5:32 pm Sale | 2025-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Venrock Healthcare Capital Partners III, L.P. | 3,226,331 5.400% | -800,000 (-19.87%) | Filing History |
| 2025-11-14 5:30 pm Purchase | 2025-09-30 | 13G | CytomX Therapeutics, Inc. CTMX | Venrock Healthcare Capital Partners III, L.P. | 15,561,500 9.400% | 2,569,000 (+19.77%) | Filing History |
| 2025-11-14 5:29 pm Sale | 2025-09-30 | 13G | Abivax S.A. ABVX | Venrock Healthcare Capital Partners III, L.P. | 576,729 0.800% | -3,034,841 (-84.03%) | Filing History |